Position in CADL
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$292,182
+$37,486 QoQ
Shares Held
59,629
+32.3% QoQ
Ownership
0.081%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CADL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ALPS ADVISORS INC holds $156,743,120 across 93 Biotechnology names. CADL ranks #85 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
496,682 | $23,825,835 | |
| 2 | KYMR |
Kymera Therapeutics, Inc.
|
66,457 | $5,535,203 | |
| 3 | CGON |
CG Oncology, Inc.
|
68,737 | $4,652,120 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
49,128 | $4,538,444 | |
| 5 | CELC |
Celcuity Inc.
|
37,663 | $4,298,854 | |
| 6 | APLS |
Apellis Pharmaceuticals, Inc.
|
104,058 | $4,186,253 | |
| 7 | XENE |
Xenon Pharmaceuticals Inc.
|
67,723 | $3,938,092 | |
| 8 | APGE |
Apogee Therapeutics, Inc.
|
45,586 | $3,836,973 |
All Filings in CADL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $292,182 | 59,629 | Shares | Defined | 2026-05-08 | |
| 2025-12-31 | $254,696 | 45,079 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $134,017 | 26,278 | Shares | Defined | 2025-11-05 | |
| 2025-06-30 | $136,847 | 27,045 | Shares | Defined | 2025-08-11 | |
| No filing history on record for this holder in this stock. | ||||||